1 May 1996 in The Cleft Palate Craniofacial Journal
Craniofacial clefts are rare among facial anomalies, with an incidence of 1.5 to 5 per 100,000 births, and 1 per 100 cases of cleft lip and palate. The Tessier No. 4 oro-ocular cleft is one of the rarest, with 33 unilateral and bilateral clefts reported in the literature. Among the bilateral clefts only 3 of 9 involved Tessier No. 4 cleft bilaterally. We report a case of bilateral Tessier No. 4 craniofacial cleft and our approach to surgical correction.
13 November 2019 in Aesthetic Plastic Surgery
18 August 2019 in Journal of Cosmetic and Laser Therapy
RF devices have frequency, power and duration setting options, it is important to make sure that the device meets the targeted values at the head output. This study was made to evaluate the RF device output value accuracy and the effects of different frequencies on the tissue heat levels. RF was applied to invitro tissues obtained from surgical operations, and invivo tissues during operations. Heat differences and depth were measured by laser/IR thermometer and thermal infrared camera. First, the output frequency and power values provided by the device were approved. Then, three three heads (monopolar, bipolar and tripolar) with three different frequencies (1,7, 20 MHz) were used. Depth of heat increase was evaluated in millimeters. The results showed that temperature increase varied between 10°C and 30°C at different depths using different frequencies. Heating of the skin with a radiofrequency device in a therapeutic dose is possible if the appropriate frequency and adequate power values are applied. Because the therapeutic temperature is close to the complication limit, the practitioner should be an expert using the device, well-knowledgeable about the regional skin structure and thickness, as well as be able to properly adjust the application doses in order to get therapeutic results.
29 November 2019 in Dermatologic Therapy
25 January 2021 in Aesthetic Surgery Journal
The clinical results of many studies on platelet-rich plasma (PRP) differ because there is a lack of standardization in PRP preparation and administration, as well as many variables such as PRP preparation methods, platelet concentration, and platelet activation. The aim of this study was to investigate a different variable that will affect PRP application results. How much PRP should be injected into the unit area of tissue for an effective PRP treatment? The study was performed on fresh surplus tissues of 20 patients that were discarded in abdominoplasty and mammoplasty operations. 9 areas that were 4cm 2 in size were marked on the skin. Fluorescein-stained PRP was injected intradermally by using 3 different gauge needles and 3 different doses (0.01, 0.03, and 0.05 ml). After injections, spreads of the fluorescent dye-covered areas in horizontal and vertical planes were measured and compared. For the horizontal plane measurements, the dye spread was measured, first from the surface of skin and a second measurement was done from the dermal surface of skin. In addition, the width and depth of the dye spread in the dermis were measured from vertical sections. Changing the needle diameter does not affect the width or depth (thickness) of the PRP spread in the dermis. Increasing the applied dose to 0.03 ml increases the spread to the width and depth (thickness). In research for evaluating the effectiveness of PRP treatments, it is necessary to report the volume of PRP to be applied per unit tissue.
27 June 2019 in Journal of Plastic Surgery and Hand Surgery
Background: Viability decreases at the distal parts with an increase in the length of flaps. In this study, we evaluated the effects of subcutaneously administered omentin on flap viability, where it is applied to distal one-third part of McFarlane flaps elevated from the rat’s dorsal skin. Materials and methods: Twenty-four adult, female, Sprague–Dawley rats were used. Subjects were divided into three groups; group 1 is the control group, group 2 received omentin 1 week before flap elevation, and group 3 received omentin 2 d before and at the day of flap elevation. About 1 cc (300 nanogram/cc) omentin applied by subcutaneous injections to the distal one-third flap. Photos are taken daily for macroscopic evaluations. The 3-mm full thickness punch biopsies at the third day and 1-cm2 biopsies at the seventh day from the middle of the one-third distal third of the flaps were taken. Necrotic and viable areas were measured. Neutrophil counting, epidermis thickness, inflammation, edema, and vascular endothelial growth factor (VEGF) immune staining were evaluated using histopathological analyses. Endothelial Nitric Oxide Synthase (eNOS) expression was performed by ELISA. Results: Omentin increased the percentage of the viable areas of flaps, epidermal thickness, number of newly formed blood vessels, and eNOS expression levels. The results showed statistical significance. Conclusions: Omentin human increases the viable areas of flaps and may be used for enhancement of flap survival.